The COVID-19 pandemic exposed and often exacerbated the significant systemic health inequities that underserved communities have faced for many years. Black Americans have been particularly affected by these inequalities. These inequities and resulting disparities foster mistrust and contribute to vaccine hesitancy.
Systemic racism is as real as any disease and we must continue to aggressively address underlying biases, correct historic wrongs, and strive for better patient experiences with institutions of power to build trust and improve patient outcomes for underserved communities. There’s not a silver bullet, but there are concrete steps our industry is taking – like PhRMA’s first-ever, industry-wide principles on clinical trial diversity – to address these issues and related barriers to care.
I recently had the opportunity to connect with Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. (USBC), which represents 310,000 Black-owned businesses nationwide, about how to improve vaccine confidence in communities of color. We spoke at a joint event our two organizations hosted that included leading scientific and medical experts.
Stephen Ubl (SU): The pandemic has hit the Black community in two big ways, through health consequences and high rates of unemployment resulting from the pandemic. What are you hearing from your fellow business leaders on the challenges of operating in this environment and trying to reopen while balancing the need to keep public health front and center?
Ron Busby, Sr. (RB): We have lost over 70,000 African Americans to the virus, but we also lost nearly 450,000 Black-owned businesses to the virus. Essential workers, which were many of the Black and Brown employees across the country, were forced to go into work with very little information and little protection. This combined with the often subpar conditions of our health care systems in many Black and Brown communities led to a great deal of unrest.
True transparency, as it relates to information on the vaccines, is critical to businesses opening back up. For us, transparent conversations like this will disseminate good information and help inform how we safely open back up.
SU: There are lots of factors and barriers that stand in the way of communities of color getting access to equitable health care, including COVID-19 vaccines. What do you see as the greatest barriers to vaccine uptake and adherence?
RB: It’s a combination of things. Many African Americans have heard about what happened in Tuskegee and have never forgotten the study. But also, we face implicit biases on a daily basis. There are racial disparities in health care, and we often face misinformation and a lack of transparency. We want to work together to make sure that people know the facts about our health care challenges, and mitigate the conversations across Black communities that may be spreading misinformation.
SU: How do we work together to earn back that trust and help ensure all Americans, including the Black community, are protected against COVID-19 and other deadly diseases?
RB: To start, we need to enhance transparency and education by speaking directly to the Black community about the issues. We need to create the opportunity for people to ask questions and hear from leaders in the community. Also, diversity in clinical trials and tests are critical. It allows us to be included on the front end of the development opposed to just the implementation. I think that rebuilds those trust factors.
SU: As you know, PhRMA has instituted the first ever industry-wide principles on clinical trial diversity. These voluntary principles are meant to help us to enhance diversity in clinical trials, to enhance our recruitment and retention and to ensure that these trial populations better reflect the disease population of those individuals who are impacted by disease. Any other thoughts you have on the importance of diversity in clinical trials?
RB: Including a diverse group in clinical trials is extremely important…From a systemic perspective, when you see people that look like you are included in the process, it gives the perspective that yes, our issues are being addressed on the front end versus the back end.
SU: As a business and community leader, I'm interested in the conversations that you're having with your peers, with your own employees about the importance of getting vaccinated. How should leaders talk to their employees about the importance of getting vaccinated so that our economy and jobs can come back?
RB: It's not just about talking, it's about actually leading. And the best way you can lead is by example. When you're talking to your staff or talking to your customers, employees, as well as your vendors, it's great to first have a knowledge of the vaccine itself so that you can talk from a place of understanding. Second, don't underestimate your influence. In many Black communities, it's those business leaders, those business owners that have gained the trust of those communities. For our leaders, you can start by going to https://usblackchambers.org/vaccine/ for more information.
To watch the full event, click here.
Stephen J. Ubl
Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. The U.S. biopharmaceutical sector directly employs more than 800,000 Americans and invests more than $100 billion in research and development annually – more than any other industry in America.
Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups – including patient and physician groups, regulators, public and private payers, and global trade organizations – to help ensure timely patient access to innovative treatments and cures. The New York Times writes, “If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl. He is more conversant with the intricacies of health policy, and more adept at the politics."
Previously, Ubl served as president and CEO of medical technology association AdvaMed, where he helped facilitate landmark reforms related to the U.S. Food and Drug Administration product review process and Medicare’s coverage and reimbursement of medical technologies. He led the industry’s defense of breakthrough R&D, successfully delaying an innovation-stifling device tax, and, in 2013, was recognized by a leading industry publication as one of 10 people to have a lasting impact on the medical technology industry.
Ubl has worked extensively with patient advocacy organizations in health policy, including longstanding service on the board of the National Health Council, a leading umbrella organization for voluntary health care organizations and has been personally involved with JDRF (formerly known as the Juvenile Diabetes Research Foundation).
He is routinely recognized as one of Washington’s most effective advocates. Ubl has been recognized on Business Insider’s “DC Healthcare Power Players” and Modern Healthcare’s “100 Most Influential People in Healthcare.” He is identified as a top health influencer by Medical Marketing & Media and PR Week magazines.
https://www.linkedin.com/in/steveubl/
President and Chief Executive Officer
Why smart vaccine policy matters
New study: HPV vaccination helps prevent cervical cancer deaths
New research reinforces the importance of hepatitis B vaccination at birth
World Immunization Week: Putting preventable diseases in the past
ICYMI: Measles resurgence could cost U.S. nearly $8 billion over five years
Why shifting childhood vaccines to “shared clinical decision-making” puts kids at risk
Changes to America’s childhood vaccine schedule fail to protect our nation's kids
New study: Measles setbacks harm health and America’s economy
Why the hepatitis B vaccine matters
Vaccines and autism: Decades of scientific evidence find no link
Why the vaccine injury program matters
Recognizing the importance of vaccination for American health and security
Answering common questions on mRNA technology
What to know about vaccine ingredients: Aluminum and thimerosal
World Immunization Week: Highlighting the importance of vaccines for public health
What you need to know: Measles and the MMR vaccine
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
Leveraging the power of vaccines to prevent antimicrobial resistance
From the emergency department to the CDC Advisory Committee: Key takeaways from ACIP’s recent meeting
The Patient Perspective: Vaccines
How to protect your children’s health this school year
New Report: Vaccines continue to drive improved health outcomes
Showcasing the promise of biopharma at ASCO 2024
World Vaccine Congress: Building on vaccine success
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
WHO Pandemic Agreement offers opportunities and risks for American innovators
New Report: 1,600 cancer treatments and vaccines in clinical development
What you should know about protecting your health this fall
What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain
Key considerations as Congress works towards PAHPA reauthorization
A conversation with Dr. Mike Ybarra on the current state of COVID-19
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
Celebrating the success of the COVID-19 vaccines, and looking to the future
PhRMA submits comments to OSTP on enhancing clinical trial diversity
What we’ve learned from three years of fighting COVID-19
U.S. must address IP and market access barriers abroad to protect American innovation
Word of the Month: What is TRIPS?
What you should know about RSV
TRIPS waiver expansion risks public health
Expanding the WTO intellectual property waiver will hurt American jobs
Word of the Month: Long COVID
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
Partnerships are driving global COVID-19 treatment access
The dangers of expanding the TRIPS waiver
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
A conversation with Barry Greene, CEO of Sage Therapeutics
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
What you need to know about newly authorized COVID-19 antiviral treatments
Guest post: Joining forces to combat the COVID-19 mental health crisis
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
Protecting U.S. innovation abroad to support economic and pandemic recovery
ICYMI: New report demonstrates growing global impact of antimicrobial resistance
Navigating the patient experience in the time of COVID-19
Global COVID-19 vaccination matters now and for the future
Understanding breakthrough COVID-19 infections
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19
The important role of antivirals in the fight against COVID-19
Understanding Long COVID-19
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
The impact of monoclonal antibodies and COVID-19 recovery
Recognizing National Immunization Awareness Month
Driving further innovation is critical to global vaccine equity
Supporting country readiness to boost global vaccine access
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine
Increasing global access to vaccines by optimizing production
Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief
Guest Post: A patient’s story of the long-term health impacts of COVID-19
Dose sharing as a part of the COVID-19 global vaccine equity strategy
Promoting global vaccine equity while protecting innovation
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
PhRMA awards $75,000 to fund initiatives to reduce health inequities
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
Americans 12 years of age and older are eligible for COVID-19 vaccines
PhRMA hosts first stakeholder workshop on clinical trial diversity
Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage Therapeutics
A year later: Reflections on the meaning of equity
ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
Supporting India during the devastating coronavirus surge
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
The Biden Administration allows politics to upend a pragmatic pandemic response
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
Reflecting on Mental Health Awareness Month
American leadership on innovation policy is essential to global health progress
Patient safety is at the heart of COVID-19 vaccine R&D
Data shows that Americans are relying on vaccines to get us through the pandemic
ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures
Diversifying clinical trials and fighting disease requires equity and trust
Building confidence in the COVID-19 vaccine through education
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
Intellectual property is the key to vaccine development, manufacturing and technology sharing
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
Fighting variants of COVID-19
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
Top five issues voters want addressed in the administration’s first 100 days
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
Lessons learned from COVID-19: The way we develop new medicines is changing
Growing trend: Increased vaccine confidence
Election insights: Common ground areas to address Americans’ health care concerns
Paper finds gaps in health data are a barrier to health equity
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
Election insights: Voter priorities in the states
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
Insights from the election: Meeting voters where they are on health care
Coming together to fight COVID-19: A conversation with Kabir K. Nath, President & CEO of Otsuka North America Pharmaceutical Bu
Guest post: How COVID-19 underscores the importance of public confidence in vaccines
Guest Post: Bringing our best to the fight against COVID-19
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
Deep dive: The issues that drove the 2020 vote
Understanding the emergency use authorization process for COVID-19 vaccines
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
Voters want to address the real drivers of health care costs for patients and the system
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
Flu Season 2020: Why it’s time to talk to your doctor today about getting a flu shot
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
Leading researchers to spotlight the critical role of biopharmaceutical R&D
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
Guest Post: How proactivity and planning helped Novartis ensure a stable supply of medicines during COVID-19
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
The 2020 We Work for Health Champion Awards showcase the best of our industry
Summer reading in the age of COVID-19
Supporting access to vaccines for Part D beneficiaries
The patient perspective navigating COVID-19
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
Executive order threatens R&D when we need it most to fight COVID-19
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
New initiative to bridge the gap on antimicrobial innovation
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
In combating COVID-19, science is how we get back to normal
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
Guest post: A post-pandemic crisis: The mental toll on America
Guest Post: From lab to jab: Vaccine development to prevent COVID-19
PhRMA awards $100,000 to fund projects that address health inequalities
The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19
What scientific experts are saying about vaccine safety
Guest Post: Honoring Asian and Pacific Islander heritage in the age of COVID-19
IP Explained: Intellectual property system working to combat COVID-19
Guest Post: What will we learn from COVID-19?
Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
Guest Post: Preserving clinical research sites during the coronavirus pandemic
Observing National Minority Health Month in the age of COVID-19
New report shows nearly 260 vaccines in development, including dozens for COVID-19
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
Guest post: Securing the health care supply chain during COVID-19
To the millions affected by COVID-19
New infographic: How we are fighting COVID-19
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
The biopharmaceutical industry’s unique role in responding to COVID-19
ICYMI: America’s biopharmaceutical companies are working 'around the clock' to beat coronavirus
COVID-19 Response: Supporting the frontline
Guest post: Looking out for the invisibly vulnerable in the time of COVID-19
America’s biopharmaceutical companies are working around the clock to beat coronavirus
Guest post: Takeda’s efforts to address COVID-19
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
ICYMI: Continued biopharmaceutical action on COVID-19
Helping those affected by the coronavirus
Why vaccines work in the fight against measles and other infectious diseases
Medicare Monday: Helping beneficiaries access vaccines
New report and event examine the new era of vaccines
Medicare Monday: Strengthening access to vaccines for seniors
"A conversation with Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in communities of color"
Vaccines
Coronavirus
Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community
"A conversation with Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in communities of color"